Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 19/20 | 0.74 |
| ▸ | GABRG2 | P18507 | 19/20 | 0.74 |
| ▸ | GABRB3 | P28472 | 19/20 | 0.74 |
| ▸ | GABRA3 | P34903 | 19/20 | 0.74 |
| ▸ | GABRA5 | P31644 | 17/20 | 0.74 |
| ▸ | GABRA2 | P47869 | 17/20 | 0.74 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.74 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.74 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7479860 | 0.88 | GABRA1 (0.83) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7473733 | 0.85 | GABRA1 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7475561 | 0.85 | GABRA1 (0.75) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2461190 | 0.85 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7476419 | 0.84 | GABRA1 (0.66) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7475087 | 0.84 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7484958 | 0.84 | GABRA1 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7967669 | 0.84 | GABRA1 (0.62) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL17368153 | 0.84 | GABRA1 (0.67) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7480594 | 0.83 | GABRA1 (0.78) | GABRA1GABRG2GABRB3GABRA3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-06-13 | — | — | US | disclosed |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | GABRA1 14/4885GABRG2 13/4885GABRB3 8/4885 |
| US-20130150351-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | GABRA1 16/4885GABRG2 13/4885GABRB3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.